Pharmaceutical company Dis-Chem’s failure to properly guide the market on its earnings did not sit well with investors — but that is not their only gripe. They are also concerned about sales and earnings and the company’s growth outlook. Dis-Chem does not have much room for missteps, given, as analysts put it, that it is "priced for perfection", at a forward p:e upwards of 30. In the past month Dis-Chem’s share price lost more than 12%, while Clicks, Dis-Chem’s more experienced and larger rival, gained 15%. At the moment, the smart money is definitely on Clicks. This is not what investors had expected. Dis-Chem’s listing in 2016 was welcomed as a strong alternative investment in the sector, and its earnings and growth trajectory was most promising, hence the high rating. But its results for the year to February were a surprise, and not in a good way. Dis-Chem’s share price fell from R37.50 prior to the release of its results to end-February to below R30, and has picked up only sligh...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now